… in remission at 8 years. And, 45% of newly diagnosed patients in this study remained in
remission … or durable as in patients who did not receive rituximab plus chemotherapy induction. …

… and optimizing treatment of follicular lymphoma. Historically considered … remission durations
of 10 or more years, and risk of dying of … of follicular lymphoma, and have confirmed durable …

… (FL) is the most common indolent non-Hodgkin lymphoma (NHL), accounting for ∼… Lymphoma
Group (NLG) demonstrated that rituximab monotherapy can produce durable remissions …

… In conclusion, ASCT is associated with high rates of durable remissions in relapsed FL,
with long-term follow-up confirming that more than 50% of transplanted patients may be …

… line therapy options for symptomatic follicular lymphoma (FL) … response rates (ORRs) and
durable remissions, 14 axi-cel … Results from ELARA indicate high and durable efficacy of tisa…

… with relapsed or refractory follicular lymphoma require thoughtful consideration of … durable
remission and manageable safety for patients with relapsed or refractory follicular lymphoma…

… Furthermore, our results support the role of ASCT as consolidation therapy at first chemosensitive
relapse/progression for FL patients providing long term durable remissions in a subset …

… -cell non-Hodgkin lymphoma (B-NHL) and B-cell acute lymphoblastic leukemia, a subset of
patients with disease refractory to available therapies will achieve durable remissions after a …

… Follicular lymphoma (FL) is the most common subtype of iNHL. … Moreover, the durability of
remission with available … outcomes, and lead to more durable remission, remains. Based on …

… Long term follow up of these trials has shown durable remissions in around 40% of patients,
demonstrating the potential of deep remissions in r/r DLBCL, including tFL [105,106]. All …